MDNC (Medinotec) Debt-to-Equity: 0.00 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDNC Medinotec Inc MDNC
24 GF Score
Price $5.00
! 1 Warning Sign
View Full Analysis

What is Medinotec Debt-to-Equity?

Medinotec MDNC 24 Debt-to-Equity is 0.00 as of May. 2026. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Medinotec's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.01 Mil. Medinotec's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.00 Mil. Medinotec's Total Stockholders Equity for the quarter that ended in May. 2026 was $5.85 Mil. Medinotec's debt to equity for the quarter that ended in May. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medinotec's Debt-to-Equity or its related term are showing as below:

During the past 5 years, the highest Debt-to-Equity Ratio of Medinotec was 0.90. The lowest was -3.37. And the median was 0.44.

MDNC's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Medinotec  (OTCPK:MDNC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Medinotec Debt-to-Equity Related Terms


Medinotec Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Medinotec's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medinotec Debt-to-Equity Chart

Medinotec Annual Data
Trend Feb22 Feb23 Feb24 Feb25 Feb26
Debt-to-Equity
-3.37 0.73 0.85 0.23 0.00

Medinotec Quarterly Data
Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.01 0.00 0.00 0.00

MDNC vs NVNO, APYX, RDGL: Debt-to-Equity Comparison

For the Medical Devices subindustry, Medinotec's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medinotec Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medinotec's Debt-to-Equity falls into.


MDNC
24GF Score
Medinotec Inc MDNC
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medinotec Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medinotec's Debt to Equity Ratio for the fiscal year that ended in Feb. 2026 is calculated as

Medinotec's Debt to Equity Ratio for the quarter that ended in May. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Medinotec (MDNC) has a Debt-to-Equity of 0.00 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medinotec and its competitors.
Is Medinotec's Debt-to-Equity too high?
Medinotec's current Debt-to-Equity is 0.00. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's Debt-to-Equity compare to NVNO and APYX?
Medinotec's Debt-to-Equity of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medinotec and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medinotec (MDNC), the current Debt-to-Equity is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medinotec Business Description

Address Stand 299 Avant Garde Avenue, 10 New Market Street, Northlands Deco Park, North Riding, Johannesburg, GT, ZAF, 2169
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score

Get the complete analysis for MDNC

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.00
Price